Lancaster General Hospital
Open enrollment with a later-stage pipeline tilt
According to ClinicalTrials.gov-derived indexes, Lancaster General Hospital sits in the top decile of US sponsors by registered trial count (#934 of 15,742 sponsors by registered trial count).
Lancaster General Hospital: 15 sponsored US clinical trials, 2 recruiting.
Lancaster General Hospital sponsors 15 registered US clinical trials on ClinicalTrials.gov, 2 of them currently recruiting, and 9 completed. 2 of these trials are in Phase 3-4 (later-stage) and 0 in Phase 1-2 (earlier-stage). The most-studied condition in this pipeline is Heart Failure, with 2 trials.
Top-decile sponsor footprint
Lancaster General Hospital ranks in the top decile of sponsors by registered trial count (#934 of 15,742 sponsors by registered trial count). Volume at this scale usually reflects a long institutional pipeline, read phase tilt and therapeutic areas below before treating it as current-year activity.
Trial completion reliability score
9 of 13 decided trials (Completed vs. Terminated on ClinicalTrials.gov) reached their planned completion (69.2%), vs. national p10 68.4% / p90 100% among 1,234 sponsors with at least 10 decided trials. Still-open trials (Recruiting, Active-not-recruiting, Not-yet-recruiting) are excluded since they have not reached an outcome yet.
Open and recent trials
15 total, page 1 of 1
Foundational Programs to Combat Clinician Stress
NCT07220421
Dilated Cardiomyopathy Detection Using AI and Screening With Mobile Technology (DCM-DETECT)
NCT06688396
Parasympathetic Augmentation Via Respiratory Training for Patients With Systolic Heart Failure
NCT05223751
Adverse Events of MRI With Abandoned Leads
NCT04478773
The Effect of Melatonin and Vitamin C on COVID-19
NCT04530539
Pediatric Concussion Outcomes
NCT04226365
Evaluation of TXA Prior to Surgery in the Geriatric Hip Fracture Population
NCT03923959
The Evaluation of the Roles of New Cardiac Imaging in Patients With Chest Pain
NCT03800862
A Whole Food Plant Diet and Its Lipidemic Effects on Primary Prevention in a Free-range Population
NCT03523247
Aromatherapy in Management of Postoperative Nausea in Post-Bariatric Surgery Patients
NCT03130218
CHF Inpatient Ambulation Trial
NCT02828553
Implementing Myocardial Computed Tomographic Perfusion in a Community Hospital Setting
NCT02756234
Fitbit / Healthy Weight Management Study
NCT02381262
Registry of Patients for MRI With Non-MRI Conditional Pacemakers and ICD Non-MRI Conditional Pacemakers and ICD
NCT02318550
Care Managers for Perinatal Depression (CMPD)
NCT01773629
Phase Distribution
| Phase | Trial count |
|---|---|
| Phase 3 | 1 |
| Phase 4 | 1 |
Where Lancaster General Hospital enrollment is open (later-stage tilt)
2 recruiting of 15 indexed (13% open); 9 completed (60%).
Phase mix: 2 late (III/IV) vs 0 early (I/II) (later-stage heavy).
Top condition: Heart Failure (2 trials), 9 others listed.
How open-pipeline share is computed
Recruiting share is recruiting_count divided by trial_count for this sponsor in the public registry export. Status can change between pulls; treat the figure as a research-attention snapshot, not product availability.
Lancaster General Hospital: open-pipeline peers nationwide
Peers matched on 15 registered trials and 13% open enrollment, not the therapeutic-area sidebar.
Lancaster General Hospital sits at or above the median trial volume and at or above the median recruiting share among these 9 nationwide peers -- the two do not always move together.
Sponsors near 15 trials (± recruiting share)
- Allakos · 15 trials · 0% recruiting
- Arbor Research Collaborative for Health · 15 trials · 33% recruiting
- Arena Pharmaceuticals · 15 trials · 0% recruiting
- Arrowhead Pharmaceuticals · 15 trials · 20% recruiting
Sponsors near 13% open enrollment (± trial volume)
- Chiesi Farmaceutici S.p.A. · 13% recruiting · 30 trials
- Dizal Pharmaceuticals · 13% recruiting · 15 trials
- Edgewise Therapeutics · 13% recruiting · 15 trials
- EpicentRx · 13% recruiting · 15 trials
Related
What to do with this Lancaster General Hospital page
15 registered trials is a research-attention snapshot, not an endorsement of Lancaster General Hospital or any single study.
- 2 of Lancaster General Hospital's trials are currently recruiting, check each one's own eligibility criteria before contacting a site. Browse recruiting trials
- Heart Failure is the condition Lancaster General Hospital studies most, compare against other sponsors active in the same condition before evaluating a specific study. See Heart Failure trials
- Bring the specific trial ID (NCT number) to your own doctor before enrolling, this page is a directory, not medical guidance. Read the trial-finding guide
Trial and recruiting counts reflect ClinicalTrials.gov registry status as of the data vintage above; individual trial eligibility and enrollment status can change.
Lancaster General Hospital pipeline card: 15 registered trials from official public datasets.Report a data error.